GLYCOMANTRA INC
Leesburg, VA · Biotech · Private
TFD100, a galectin-3 antagonist small molecule therapeutic derived from natural carbohydrates for treating insulin resistance and type 2 diabetes
glycomantra.com →- Grants
- $8.1M
- 13 awards
- Sector median: 1
- Raised
- —
- No Form D on record
- Contracts
- —
- No federal contracts on record
- Patents
- 6
- 2 granted · 4 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓201520172019202120232025
| Date | Event | Source | Amount |
|---|---|---|---|
| Federal grant | Department of Health and Human Services · Phase I · Targeting galectin-3 for prostate cancer therapy | $224,881 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeting galectin-3 for prostate cancer therapy | $264,881 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeting galectin-3 for prostate cancer therapy | $40,000 | |
| Federal grant | Department of Health and Human Services · Phase I · GRIM19 for head and neck cancer therapy | $298,517 | |
| Federal grant· 1 of 2 same day | Department of Health and Human Services · Phase I · Targeting galectin-3 for treatment of NASH mediated fibrosis | $298,490 | |
| Federal grant· 2 of 2 same day | Department of Health and Human Services · Phase I · Targeting galectin-3 to overcome drug resistance in metastatic prostate cancer therapy | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeting galectin-3 for treatment of NASH mediated fibrosis | $298,490 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeting galectin-3 to overcome insulin resistance in type 2 diabetes | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeting galectin-3 to intervene COVID-19 | $300,000 | |
| Federal grant | Department of Health and Human Services · Phase I · Targeting galectin-3 to intervene COVID-19 | $296,637 | |
| Federal grant | Department of Health and Human Services · Phase II · Targeting galectin-3 to overcome insulin resistance in type 2 diabetes | $1,810,483 | |
| Federal grant | Department of Health and Human Services · Phase II · Targeting galectin-3 to overcome insulin resistance in type 2 diabetes | $1,810,483 | |
| Federal grant | Department of Health and Human Services · Phase II · Targeting galectin-3 to overcome insulin resistance in type 2 diabetes | $1,864,171 |
Federal grant · SBIR/STTR
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 3015 | Recodagen LLC | — | — |
| 3016 | DeepMind | — | — |
| 3017 | MAA Laboratories Inc. | — | — |
| 3018 | GLYCOMANTRA INC | — | — |
| 3019 | AQUILUS PHARMACEUTICALS INC | — | — |
| 3020 | Dualogics LLC | — | — |
| 3021 | Deep Cell Industries Inc. | — | $771K |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Patents
- Compositions And Methods For Treating Aging-related Metabolic And Neurological Disordersapplication
- Compositions And Methods For Treating Cancer With Andrographolide And Melatonin Combination Therapygranted
- Compositions And Methods For Treating Metabolic Disordersgranted
- Compositions And Methods For Treating Metabolic Disordersapplication
- Compositions And Methods For Treating Metabolic Disordersapplication
- Compositions And Methods For Treating Cancer With Andrographolide And Melatonin Combination Therapyapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.